ANDA Refuse-to-Receive Challenges Become More Common – And More Successful
Executive Summary
Teva official calls for improved staff consistency as a new GDUFA headache emerges for FDA.
You may also be interested in...
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
Four Rules For Being A Consistent US FDA Reviewer From Peter Stein
Amid concerns Office of New Drugs reorganization will result in sponsors receiving conflicting advice, new director offers several items already contemplated to prevent such problems.
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.